{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:12Z","timestamp":1793157912634,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.canlet.2024.216908","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:52:41Z","timestamp":1714063961000},"page":"216908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors"],"prefix":"10.1016","volume":"592","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-5560","authenticated-orcid":false,"given":"Xiaopeng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216908_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.canlet.2024.216908_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2024.216908_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11102-023-01298-4","article-title":"Refractory nonfunctioning pituitary adenomas","volume":"26","author":"Kolitz","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.canlet.2024.216908_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.21037\/gs-20-873","article-title":"Diagnosis and treatment of refractory pituitary adenomas: a narrative review","volume":"10","author":"Liu","year":"2021","journal-title":"Gland Surg."},{"key":"10.1016\/j.canlet.2024.216908_bib7","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib10","first-page":"105","article-title":"Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion","author":"Principe","year":"2020","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2024.216908_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1507\/endocrj.45.357","article-title":"Prevalence of lymphocytic infiltrate in 1400 pituitary adenomas","volume":"45","author":"Heshmati","year":"1998","journal-title":"Endocr. J."},{"key":"10.1016\/j.canlet.2024.216908_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1210\/jc.2009-1583","article-title":"Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma","volume":"95","author":"Lupi","year":"2010","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2024.216908_bib13","doi-asserted-by":"crossref","first-page":"e3207","DOI":"10.1210\/clinem\/dgaa449","article-title":"The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness","volume":"105","author":"Wang","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2024.216908_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11060-020-03636-z","article-title":"Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas","volume":"149","author":"Zhou","year":"2020","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01114-3","article-title":"Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression","volume":"24","author":"Mei","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.canlet.2024.216908_bib16","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216908_bib17","first-page":"7","article-title":"Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours","author":"Marques","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/j.canlet.2024.216908_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12020-019-02145-y","article-title":"Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours","volume":"67","author":"Iacovazzo","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.canlet.2024.216908_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11060-020-03476-x","article-title":"In silico analysis of the immunological landscape of pituitary adenomas","volume":"147","author":"Yeung","year":"2020","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11060-023-04382-8","article-title":"Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset","volume":"163","author":"Luo","year":"2023","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib21","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.7150\/thno.53749","article-title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.216908_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1215\/15228517-2008-104","article-title":"Regulatory T cells and the PD-L1\/PD-1 pathway mediate immune suppression in malignant human brain tumors","volume":"11","author":"Jacobs","year":"2009","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.598887","article-title":"Alterations in CD8(+) tregs, CD56(+) natural killer cells and IL-10 are associated with invasiveness of nonfunctioning pituitary adenomas (NFPAs)","volume":"27","author":"Huang","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.canlet.2024.216908_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-18-3486","article-title":"Targeting PD-L1 initiates effective antitumor immunity in a murine model of cushing disease","volume":"26","author":"Kemeny","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216908_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13073-023-01267-3","article-title":"Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors","volume":"16","author":"Yan","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.canlet.2024.216908_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.canlet.2024.216908_bib27","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00262-021-03080-6","article-title":"The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor","volume":"71","author":"Nie","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.216908_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and Treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib29","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1038\/s41388-019-0779-5","article-title":"Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors","volume":"38","author":"Barry","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216908_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","article-title":"The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy","volume":"139","author":"Wang","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/030089169007600605","article-title":"Mononuclear cell infiltrate and HLA-Dr expression in 28 pituitary adenomas","volume":"76","author":"Rossi","year":"1990","journal-title":"Tumori"},{"key":"10.1016\/j.canlet.2024.216908_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1151714","article-title":"PD-L1 and tumor-infiltrating CD8(+) lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib33","first-page":"13","article-title":"Targeting the tumor immune microenvironment could become a potential therapeutic modality for aggressive pituitary adenoma","author":"Yang","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.canlet.2024.216908_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050695","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2024.216908_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-007-0066-2","article-title":"Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas","volume":"11","author":"Gong","year":"2008","journal-title":"Pituitary"},{"key":"10.1016\/j.canlet.2024.216908_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00401-007-0279-5","article-title":"MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy","volume":"115","author":"Kovacs","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2024.216908_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib38","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.216908_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1348-0421.13041","article-title":"Macrophage colony-stimulating factor potentially induces recruitment and maturation of macrophages in recurrent pituitary neuroendocrine tumors","volume":"67","author":"Matsuzaki","year":"2023","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib40","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216908_bib41","first-page":"31","article-title":"\u0421ytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas","author":"Sabini","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/EJE-21-1183","article-title":"Single-cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior","volume":"187","author":"Zhang","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib43","article-title":"Multi-omics investigations revealed underlying molecular mechanisms associated with tumor stiffness and identified sunitinib as a potential therapy for reducing stiffness in pituitary adenomas","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.216908_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2024.216908_bib45","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41416-022-02084-y","article-title":"Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy","volume":"128","author":"Wang","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib46","first-page":"12","article-title":"The upregulation of molecules related to tumor immune escape in human pituitary adenomas","author":"Xi","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12022-021-09673-2","article-title":"PD-L1 is preferentially expressed in PIT-1 positive pituitary neuroendocrine tumours","volume":"32","author":"Turchini","year":"2021","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.canlet.2024.216908_bib48","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00262-020-02611-x","article-title":"Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor","volume":"69","author":"Suteau","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.216908_bib49","first-page":"21","article-title":"MSH6\/2 and PD-L1 expressions are associated with tumor growth and invasiveness in silent pituitary adenoma subtypes","author":"Uraki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216908_bib50","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216908_bib56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib58","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/ERC-19-0327","article-title":"Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness","volume":"26","author":"Marques","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib61","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.immuni.2016.09.016","article-title":"Metabolic reprogramming mediated by the mTORC2-IRF4 signaling Axis is essential for macrophage alternative activation","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216908_bib62","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","article-title":"The role of CXCL family members in different diseases","volume":"9","author":"Zhou","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216908_bib63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216908_bib64","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.18632\/oncotarget.26775","article-title":"Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes","volume":"10","author":"Yagnik","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216908_bib65","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","article-title":"The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, cushing's disease and endocrine-inactive subtypes","volume":"24","author":"Salomon","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216908_bib66","first-page":"20","article-title":"Biomarker discovery for immunotherapy of pituitary adenomas: enhanced robustness and prediction ability by modern computational tools","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216908_bib67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3803\/EnM.2019.34.3.314","article-title":"Transcriptome analysis identifies an attenuated local immune response in invasive nonfunctioning pituitary adenomas","volume":"34","author":"Kim","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.canlet.2024.216908_bib68","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1073\/pnas.0237312100","article-title":"Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad\/estrogen receptor crosstalk","volume":"100","author":"Paez-Pereda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216908_bib69","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2024.216908_bib70","article-title":"Screening and identification of key microenvironment-related genes in non-functioning pituitary adenoma","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.canlet.2024.216908_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13263","article-title":"CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs","volume":"35","author":"Chiloiro","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib72","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.wneu.2018.11.021","article-title":"A novel mutation of Aryl hydrocarbon receptor interacting protein gene associated with familial isolated pituitary adenoma mediates tumor invasion and growth hormone hypersecretion","volume":"123","author":"Cai","year":"2019","journal-title":"World Neurosurg."},{"key":"10.1016\/j.canlet.2024.216908_bib73","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00441-016-2564-x","article-title":"Identification of M2 macrophages in anterior pituitary glands of normal rats and rats with estrogen-induced prolactinoma","volume":"368","author":"Fujiwara","year":"2017","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.canlet.2024.216908_bib74","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing's disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2024.216908_bib75","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib76","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41416-022-02126-5","article-title":"Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-\u03b3-induced tumour-associated fibroblasts remodelling","volume":"128","author":"Lyu","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib77","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/jnen\/nlx072","article-title":"Aggressive behavior in silent subtype III pituitary adenomas may depend on suppression of local immune response: a whole transcriptome analysis","volume":"76","author":"Richardson","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.canlet.2024.216908_bib78","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.3390\/curroncol30060401","article-title":"The role of immunotherapy in the treatment of rare central nervous system tumors","volume":"30","author":"Rodriguez","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216908_bib80","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2024.216908_bib82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216908_bib83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216908_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101712","article-title":"Immunotherapy in pituitary carcinomas and aggressive pituitary tumors","volume":"36","author":"Raverot","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2024.216908_bib86","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2021.01.011","article-title":"Melanoma models for the next generation of therapies","volume":"39","author":"Patton","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216908_bib87","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216908_bib88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216908_bib89","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216908_bib90","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.216908_bib91","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2024.216908_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76555-8","article-title":"Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors","volume":"10","author":"Taniguchi-Ponciano","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.216908_bib93","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib94","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib95","first-page":"8","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","author":"Majd","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib96","first-page":"10","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","author":"Duhamel","year":"2020","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.canlet.2024.216908_bib97","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.14645","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","volume":"98","author":"Goichot","year":"2023","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib98","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"key":"10.1016\/j.canlet.2024.216908_bib99","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.canlet.2024.216908_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.576027","article-title":"Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib101","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?","volume":"184","author":"Sol","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216908_bib102","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.canlet.2024.216908_bib103","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2024.216908_bib104","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/ERC-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review","volume":"29","author":"Ilie","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2024.216908_bib105","first-page":"14","article-title":"Immunotherapy for aggressive and metastatic pituitary neuroendocrine tumors (PitNETs): state-of-the art","author":"Feola","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216908_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6717912","article-title":"The value of PD-L1 expression in predicting the efficacy of anti-PD-1 or anti-PD-L1 therapy in patients with cancer: a systematic review and meta-analysis","volume":"2020","author":"Chen","year":"2020","journal-title":"Dis. Markers"},{"key":"10.1016\/j.canlet.2024.216908_bib107","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216908_bib108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000100405","article-title":"Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report","volume":"13","author":"Hazrati","year":"2006","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.canlet.2024.216908_bib109","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216908_bib111","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/neuonc\/noab005","article-title":"Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma","volume":"23","author":"Guo","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216908_bib112","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/POLD1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216908_bib113","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in cancer immunotherapy","volume":"8","author":"Markl","year":"2022","journal-title":"Trends Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352400301X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352400301X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T21:10:40Z","timestamp":1716412240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352400301X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":113,"alternative-id":["S030438352400301X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216908","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216908"}}